Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSZQAK)

Drug Name
Amphetamine Drug Info
Synonyms Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Depression 6A70-6A7Z Approved [2]
Narcolepsy 7A20 Approved [2]
Obesity 5B81 Approved [2]
Cross-matching ID
PubChem CID
3007
ChEBI ID
CHEBI:2679
CAS Number
CAS 300-62-9
TTD Drug ID
DMSZQAK
VARIDT Drug ID
DR00084
INTEDE Drug ID
DR0106
ACDINA Drug ID
D00036

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Trace amine-associated receptor-1 (TAAR1) TTIU98M TAAR1_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID Highest Status REF
Sodium-dependent dopamine transporter (SLC6A3) DT3BA8L SC6A3_HUMAN Approved [4]
Sodium-dependent noradrenaline transporter (SLC6A2) DT9JBVI SC6A2_HUMAN Approved [4]
Organic cation/carnitine transporter 2 (SLC22A5) DT3HUVD S22A5_HUMAN Approved [5]
Organic cation transporter 3 (SLC22A3) DT6201N S22A3_HUMAN Approved [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Approved [7]
Tyramine oxidase (tynA) DEB3TNR AMO_ECOLI Approved [8]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Sodium-dependent noradrenaline transporter (SLC6A2) DTP NET 2.322 3.263 2.632 3.018
Organic cation transporter 3 (SLC22A3) DTP `OCT3 5.289 1.963 3.472 3.621
Organic cation/carnitine transporter 2 (SLC22A5) DTP OCTN2 6.613 7.705 8.234 8.098
Sodium-dependent dopamine transporter (SLC6A3) DTP DAT1 4 2.609 5.233 3.7
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 3.307 5.005 3.921 5.327
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Attention deficit hyperactivity disorder
ICD Disease Classification 6A05.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Trace amine-associated receptor-1 (TAAR1) DTT TAAR1 6.12E-01 -0.01 -0.06
Sodium-dependent noradrenaline transporter (SLC6A2) DTP NET 7.05E-01 7.02E-03 6.74E-02
Organic cation transporter 3 (SLC22A3) DTP SLC22A3 3.72E-01 5.29E-02 3.62E-01
Organic cation/carnitine transporter 2 (SLC22A5) DTP OCTN2 1.13E-01 -5.69E-03 -4.16E-02
Sodium-dependent dopamine transporter (SLC6A3) DTP DAT1 4.17E-01 4.04E-03 2.45E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Amphetamine FDA Label
3 Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
4 Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
5 Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
6 Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
7 Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
8 Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jan 30.